Late Adverse Effects after Treatment for Childhood Acute Leukemia
(2024) In Acta Medica Academica 53(1). p.59-80- Abstract
The aim of this review is to raise awareness and knowledge among healthcare professionals and policymakers about late adverse effects in survivors of childhood leukemia. With contemporary treatment, over 90% of children with acute lymphoblastic leukemia (ALL) and over 60% with acute myeloid leukemia (AML) are cured. Large cohort studies demonstrate that 20% of ALL and most AML survivors have at least one chronic health condition by 20-25 years after diagnosis. These are life-changing or threatening in some survivors and contribute to increased premature mortality. We describe the frequency, causes, clinical features, and natural history of the most frequent and severe late adverse effects in childhood leukemia survivors, including... (More)
The aim of this review is to raise awareness and knowledge among healthcare professionals and policymakers about late adverse effects in survivors of childhood leukemia. With contemporary treatment, over 90% of children with acute lymphoblastic leukemia (ALL) and over 60% with acute myeloid leukemia (AML) are cured. Large cohort studies demonstrate that 20% of ALL and most AML survivors have at least one chronic health condition by 20-25 years after diagnosis. These are life-changing or threatening in some survivors and contribute to increased premature mortality. We describe the frequency, causes, clinical features, and natural history of the most frequent and severe late adverse effects in childhood leukemia survivors, including subsequent malignant neoplasms, metabolic toxicity, gonadotoxicity and impaired fertility, endocrinopathy and growth disturbances, bone toxicity, central and peripheral neurotoxicity, cardiotoxicity, psychosocial late effects, accelerated ageing and late mortality. The wide range of late effects in survivors of haemopoietic stem cell transplant is highlighted. Recent developments informing the approach to long-term survivorship care are discussed, including electronic personalized patient-specific treatment summaries and care plans such as the Survivor Passport (SurPass), surveillance guidelines and models of care. The importance of ongoing vigilance is stressed given the increasing use of novel targeted drugs with limited experience of long-term outcomes. Conclusion. It is vital to raise awareness of the existence and severity of late effects of childhood leukemia therapy among parents, patients, health professionals, and policymakers. Structured long-term surveillance recommendations are necessary to standardize follow-up care.
(Less)
- author
- organization
- publishing date
- 2024-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Acute Leukemia, Child, Late Effects, Long-Term Follow-Up, Survivor
- in
- Acta Medica Academica
- volume
- 53
- issue
- 1
- pages
- 22 pages
- external identifiers
-
- scopus:85198416256
- pmid:38984700
- ISSN
- 1840-1848
- DOI
- 10.5644/ama2006-124.438
- language
- English
- LU publication?
- yes
- id
- 9a4de1c5-b75b-4b59-8129-2493d30b7ffb
- date added to LUP
- 2024-10-04 10:25:42
- date last changed
- 2024-10-04 10:26:40
@article{9a4de1c5-b75b-4b59-8129-2493d30b7ffb,
abstract = {{<p>The aim of this review is to raise awareness and knowledge among healthcare professionals and policymakers about late adverse effects in survivors of childhood leukemia. With contemporary treatment, over 90% of children with acute lymphoblastic leukemia (ALL) and over 60% with acute myeloid leukemia (AML) are cured. Large cohort studies demonstrate that 20% of ALL and most AML survivors have at least one chronic health condition by 20-25 years after diagnosis. These are life-changing or threatening in some survivors and contribute to increased premature mortality. We describe the frequency, causes, clinical features, and natural history of the most frequent and severe late adverse effects in childhood leukemia survivors, including subsequent malignant neoplasms, metabolic toxicity, gonadotoxicity and impaired fertility, endocrinopathy and growth disturbances, bone toxicity, central and peripheral neurotoxicity, cardiotoxicity, psychosocial late effects, accelerated ageing and late mortality. The wide range of late effects in survivors of haemopoietic stem cell transplant is highlighted. Recent developments informing the approach to long-term survivorship care are discussed, including electronic personalized patient-specific treatment summaries and care plans such as the Survivor Passport (SurPass), surveillance guidelines and models of care. The importance of ongoing vigilance is stressed given the increasing use of novel targeted drugs with limited experience of long-term outcomes. Conclusion. It is vital to raise awareness of the existence and severity of late effects of childhood leukemia therapy among parents, patients, health professionals, and policymakers. Structured long-term surveillance recommendations are necessary to standardize follow-up care.</p>}},
author = {{Roganovic, Jelena and Haupt, Riccardo and Bárdi, Edit and Hjorth, Lars and Michel, Gisela and Pavasovic, Vesna and Scheinemann, Katrin and van der Pal, Helena J.H. and Zaletel, Lorna Zadravec and Amariutei, Ana E. and Skinner, Roderick}},
issn = {{1840-1848}},
keywords = {{Acute Leukemia; Child; Late Effects; Long-Term Follow-Up; Survivor}},
language = {{eng}},
number = {{1}},
pages = {{59--80}},
series = {{Acta Medica Academica}},
title = {{Late Adverse Effects after Treatment for Childhood Acute Leukemia}},
url = {{http://dx.doi.org/10.5644/ama2006-124.438}},
doi = {{10.5644/ama2006-124.438}},
volume = {{53}},
year = {{2024}},
}